These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 22331221

  • 1. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S.
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [Abstract] [Full Text] [Related]

  • 2. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4806-15. PubMed ID: 25052479
    [Abstract] [Full Text] [Related]

  • 3. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR.
    Hell J Nucl Med; 2014 Sep 15; 17(2):90-6. PubMed ID: 24997081
    [Abstract] [Full Text] [Related]

  • 4. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
    Frings V, Yaqub M, Hoyng LL, Golla SS, Windhorst AD, Schuit RC, Lammertsma AA, Hoekstra OS, Smit EF, Boellaard R, QuIC-ConCePT Consortium.
    J Nucl Med; 2014 Sep 15; 55(9):1417-23. PubMed ID: 24970910
    [Abstract] [Full Text] [Related]

  • 5. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    Dai D, Li XF, Wang J, Liu JJ, Zhu YJ, Zhang Y, Wang Q, Xu WG.
    Int J Cancer; 2016 Feb 15; 138(4):1003-12. PubMed ID: 26334931
    [Abstract] [Full Text] [Related]

  • 6. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A.
    PLoS One; 2008 Feb 15; 3(12):e3908. PubMed ID: 19079597
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.
    Int J Cancer; 2012 May 15; 130(10):2445-54. PubMed ID: 21732342
    [Abstract] [Full Text] [Related]

  • 8. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
    Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S.
    Clin Cancer Res; 2008 Aug 15; 14(16):5209-19. PubMed ID: 18698039
    [Abstract] [Full Text] [Related]

  • 9. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
    Suleiman AA, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, Wolf J, Nogova L, Fuhr U.
    J Thorac Oncol; 2015 Jan 15; 10(1):84-92. PubMed ID: 25226426
    [Abstract] [Full Text] [Related]

  • 10. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, Wang YY.
    BMC Cancer; 2016 Jul 18; 16():491. PubMed ID: 27431492
    [Abstract] [Full Text] [Related]

  • 11. Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
    Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas R, Neumaier B, Dietlein M, Wolf J.
    Lung Cancer; 2012 Sep 18; 77(3):617-20. PubMed ID: 22726919
    [Abstract] [Full Text] [Related]

  • 12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 18; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 13. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
    Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, Papachristou I, Heukamp L, Büttner R, Boellaard R, Lammertsma AA, Querings S, Stoelben E, Engel-Riedel W, Neumaier B, Wolf J.
    PLoS One; 2013 Jun 18; 8(1):e53081. PubMed ID: 23308140
    [Abstract] [Full Text] [Related]

  • 14. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Jun 18; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 15. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 18; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C.
    J Nucl Med; 2011 Dec 18; 52(12):1871-7. PubMed ID: 22065872
    [Abstract] [Full Text] [Related]

  • 17. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND, Heidari P, Kunawudhi A, Sequist LV, Mahmood U.
    Technol Cancer Res Treat; 2016 Apr 18; 15(2):234-42. PubMed ID: 25759424
    [Abstract] [Full Text] [Related]

  • 18. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 18; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 20. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
    Meng X, Loo BW, Ma L, Murphy JD, Sun X, Yu J.
    J Nucl Med; 2011 Oct 26; 52(10):1573-9. PubMed ID: 21903741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.